These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 24722365)

  • 1. A quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivity.
    Qi H; Olson CA; Wu NC; Ke R; Loverdo C; Chu V; Truong S; Remenyi R; Chen Z; Du Y; Su SY; Al-Mawsawi LQ; Wu TT; Chen SH; Lin CY; Zhong W; Lloyd-Smith JO; Sun R
    PLoS Pathog; 2014 Apr; 10(4):e1004064. PubMed ID: 24722365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
    Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir.
    Fernandes Campos GR; Ward J; Chen S; Bittar C; Vilela Rodrigues JP; Martinelli ALC; Souza FF; Pereira LRL; Rahal P; Harris M
    J Gen Virol; 2021 Jan; 102(1):. PubMed ID: 33141008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A.
    Sun JH; O'Boyle DR; Fridell RA; Langley DR; Wang C; Roberts SB; Nower P; Johnson BM; Moulin F; Nophsker MJ; Wang YK; Liu M; Rigat K; Tu Y; Hewawasam P; Kadow J; Meanwell NA; Cockett M; Lemm JA; Kramer M; Belema M; Gao M
    Nature; 2015 Nov; 527(7577):245-8. PubMed ID: 26536115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.
    Wang C; Jia L; Huang H; Qiu D; Valera L; Huang X; Sun JH; Nower PT; O'Boyle DR; Gao M; Fridell RA
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1588-90. PubMed ID: 22203595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection.
    Zhou N; Hernandez D; Ueland J; Yang X; Yu F; Sims K; Yin PD; McPhee F
    J Infect Dis; 2016 Jan; 213(2):206-15. PubMed ID: 26170396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides.
    Chukkapalli V; Berger KL; Kelly SM; Thomas M; Deiters A; Randall G
    Virology; 2015 Feb; 476():168-179. PubMed ID: 25546252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.
    Wang C; Sun JH; O'Boyle DR; Nower P; Valera L; Roberts S; Fridell RA; Gao M
    Antimicrob Agents Chemother; 2013 May; 57(5):2054-65. PubMed ID: 23403428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir.
    Pelosi LA; Voss S; Liu M; Gao M; Lemm JA
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5230-9. PubMed ID: 22850513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.
    Wang C; Jia L; O'Boyle DR; Sun JH; Rigat K; Valera L; Nower P; Huang X; Kienzle B; Roberts S; Gao M; Fridell RA
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5155-63. PubMed ID: 24936600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus NS5A inhibitors and drug resistance mutations.
    Nakamoto S; Kanda T; Wu S; Shirasawa H; Yokosuka O
    World J Gastroenterol; 2014 Mar; 20(11):2902-12. PubMed ID: 24659881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice.
    Lee SH; Moon JS; Pak BY; Kim GW; Lee W; Cho H; Kim S; Kim SJ; Oh JW
    Sci Rep; 2018 Aug; 8(1):12469. PubMed ID: 30127498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.
    Gottwein JM; Jensen SB; Li YP; Ghanem L; Scheel TK; Serre SB; Mikkelsen L; Bukh J
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1291-303. PubMed ID: 23274664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life.
    Guedj J; Dahari H; Rong L; Sansone ND; Nettles RE; Cotler SJ; Layden TJ; Uprichard SL; Perelson AS
    Proc Natl Acad Sci U S A; 2013 Mar; 110(10):3991-6. PubMed ID: 23431163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures.
    Lemm JA; Leet JE; O'Boyle DR; Romine JL; Huang XS; Schroeder DR; Alberts J; Cantone JL; Sun JH; Nower PT; Martin SW; Serrano-Wu MH; Meanwell NA; Snyder LB; Gao M
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3795-802. PubMed ID: 21576451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daclatasvir Prevents Hepatitis C Virus Infectivity by Blocking Transfer of the Viral Genome to Assembly Sites.
    Boson B; Denolly S; Turlure F; Chamot C; Dreux M; Cosset FL
    Gastroenterology; 2017 Mar; 152(4):895-907.e14. PubMed ID: 27932311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of antiviral effects of novel NS5A inhibitors in hepatitis C virus cell culture system with full-genome infectious clones.
    Murayama A; Fujiwara K; Yamada N; Shiina M; Aly HH; Masaki T; Muramatsu M; Wakita T; Kato T
    Antiviral Res; 2018 Oct; 158():161-170. PubMed ID: 30118732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy.
    Lee C
    Arch Pharm Res; 2011 Sep; 34(9):1403-7. PubMed ID: 21975800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
    Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
    Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir.
    McPhee F; Hernandez D; Yu F; Ueland J; Monikowski A; Carifa A; Falk P; Wang C; Fridell R; Eley T; Zhou N; Gardiner D
    Hepatology; 2013 Sep; 58(3):902-11. PubMed ID: 23504694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.